Abstract 138P
Background
Adolescent and young adults (AYAs), defined as those aged 15-39 years old, are an underrepresented patient population in sarcomas. Currently, clinicopathologic characteristics of AYA sarcoma patients in the Philippines have not been reported in medical literature. In 2021, the University of the Philippines Manila Sarcoma Consortium was established which initiated the data collection for the Philippine General Hospital Sarcoma registry. Utilizing existing data from the registry, this study aimed to profile the clinicopathologic characteristics and outcomes of AYA patients diagnosed with sarcomas.
Methods
A retrospective cohort study design was used for the study. Data including demographic characteristics, histopathologic diagnosis, tumor location, disease stage, treatment details, Overall Survival (OS), and Disease-free survival (DFS) were obtained.
Results
A total of 84 patients were included in the registry with a median age of 25 years old with an equal sex distribution. Most patients (56%) presented with localized disease while 33% of patients presented with de novo metastatic disease (33%). Among those with metastatic disease, the most common site of metastasis was the lung (89%). The prevalent soft tissue sarcoma diagnoses were synovial sarcoma and rhabdomyosarcoma, accounting for 14.5% and 16.7%, respectively. While osteosarcoma is the most prevalent form of bone sarcoma comprising 75% of the sampled population. Among the patients treated with curative intent, 21 patients (42%) had tumor progression or recurrence. The three-year over-all survival rate for AYA sarcoma patients is reported at 46.6%, which is below other western studies that report OS rates at 60-80% and Asian studies that report OS rates at 50-60%.
Conclusions
Based from the registry, AYA sarcoma patients in the Philippines have poorer survival outcomes compared to western and other Asian populations groups which may be attributed to factors of tumor biology and treatment variability. This study sets the stage for additional research to further characterize AYA sarcoma patients, their unique experiences and unmet needs that need to be addressed to improve clinical outcomes in the Philippine setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of the Philippines Manila Sarcoma Consortium.
Funding
University of the Philippines Manila Sarcoma Consortium.
Disclosure
All authors have declared no conflicts of interest.